George Kemble was promoted to vice president of research and development and general manager of MedImmune Vaccines, Inc's California site in August 2004. After working as a staff scientist and senior scientist, Dr. Kemble was promoted to director of research in 1999, and senior director in 2002. Over the past 11 years at MedImmune, he has led several programs including one aimed at developing a vaccine to prevent mental retardation and hearing loss in newborns caused by cytomegalovirus. As principle investigator, Dr. Kemble obtained approximately $1 million in funding through Small Business Innovation Research grants from the National Institutes of Health to conduct this program. Dr. Kemble also continues to lead the research program aimed at understanding the basic mechanisms of attenuation and immunogenicity for MedImmune's FluMist® vaccine. Dr. Kemble received his undergraduate degree in biology from the University of Santa Clara, his PhD from the Department of Microbiology and Immunology at Stanford University, and completed a postdoctoral fellowship at the University of California, San Francisco in virology and the mechanisms that allow influenza virus entry into cells. Dr. Kemble has published approximately 20 articles in peer-reviewed journals and has received numerous professional awards.
